Date published: 2026-4-5

1-800-457-3801

SCBT Portrait Logo
Seach Input

PTP-MEG1 Inhibitors

PTP-MEG1 inhibitors are a class of chemical compounds that target the protein tyrosine phosphatase non-receptor type 14 (PTPN14), commonly referred to as PTP-MEG1. PTP-MEG1 is part of the protein tyrosine phosphatase (PTP) family, which plays a crucial role in cellular signaling by dephosphorylating tyrosine residues on target proteins, thus acting as a key regulator of numerous biological processes. The PTP-MEG1 enzyme is particularly involved in pathways associated with cytoskeletal organization, cell migration, and various signal transduction processes. Inhibitors of PTP-MEG1 function by blocking its phosphatase activity, thereby modulating the downstream signaling pathways that rely on PTP-MEG1's regulation of phosphorylation states. Structurally, these inhibitors are designed to bind to the active site of PTP-MEG1, either competitively or through allosteric mechanisms, which hinders its ability to catalyze the removal of phosphate groups from specific substrate proteins.

The chemical structure of PTP-MEG1 inhibitors is diverse, often featuring scaffolds that enhance their affinity and specificity for the enzyme's active site. Many inhibitors possess a core structure that mimics the phosphate moiety or employs molecular features to interact with the unique pocket architecture of PTP-MEG1. Additionally, structural optimization to improve bioavailability, potency, and selectivity has led to a variety of derivatives that can modulate the enzyme's activity with high precision. The binding interactions between PTP-MEG1 inhibitors and the phosphatase domain are a key focus for researchers, aiming to elucidate the conformational changes induced upon binding and to understand how these changes affect the phosphatase's overall function. By studying PTP-MEG1 inhibitors, researchers gain insights into the regulatory mechanisms of phosphatases and the broader implications of tyrosine phosphorylation in cellular processes, providing valuable information on cellular signal modulation and protein interaction dynamics.

SEE ALSO...

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

5-Azacytidine

320-67-2sc-221003
500 mg
$280.00
4
(1)

5-Azacytidine could potentially downregulate PTP-MEG1 expression by hypomethylating the gene's promoter, thereby reducing its transcriptional activity in the cell.

Trichostatin A

58880-19-6sc-3511
sc-3511A
sc-3511B
sc-3511C
sc-3511D
1 mg
5 mg
10 mg
25 mg
50 mg
$152.00
$479.00
$632.00
$1223.00
$2132.00
33
(3)

By inhibiting histone deacetylases, Trichostatin A may promote acetylation of histones near the PTP-MEG1 gene, which could lead to a decrease in the gene's expression by altering chromatin structure.

Retinoic Acid, all trans

302-79-4sc-200898
sc-200898A
sc-200898B
sc-200898C
500 mg
5 g
10 g
100 g
$66.00
$325.00
$587.00
$1018.00
28
(1)

Retinoic acid might downregulate PTP-MEG1 by binding to retinoic acid receptors that interact with the gene's promoter, thereby decreasing its transcriptional activity.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$63.00
$158.00
$326.00
233
(4)

Rapamycin could inhibit the expression of PTP-MEG1 by hindering the mTOR pathway, which is often involved in the translation control of many genes, including those related to cell differentiation.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$123.00
$400.00
148
(1)

This PI3K inhibitor may lead to a decrease in PTP-MEG1 expression by attenuating the PI3K/AKT pathway, which is crucial for the translation of many growth-related proteins.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$90.00
$349.00
284
(5)

SB 203580 could decrease PTP-MEG1 expression by blocking p38 MAPK activity, which may be necessary for the transcription of genes involved in cell cycle regulation and stress response.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

Inhibition of JNK by SP600125 may result in reduced transcriptional activity of stress response genes, potentially including PTP-MEG1, thereby lowering its expression levels.

Gefitinib

184475-35-2sc-202166
sc-202166A
sc-202166B
sc-202166C
100 mg
250 mg
1 g
5 g
$63.00
$114.00
$218.00
$349.00
74
(2)

Gefitinib could downregulate PTP-MEG1 by inhibiting EGFR tyrosine kinase activity, which may disrupt downstream signaling pathways essential for the gene's expression.

Imatinib

152459-95-5sc-267106
sc-267106A
sc-267106B
10 mg
100 mg
1 g
$26.00
$119.00
$213.00
27
(1)

Imatinib might lower PTP-MEG1 expression by targeting BCR-ABL tyrosine kinase, which is involved in a signaling cascade that can control the expression of various genes.

Suberoylanilide Hydroxamic Acid

149647-78-9sc-220139
sc-220139A
100 mg
500 mg
$133.00
$275.00
37
(2)

Suberoylanilide Hydroxamic Acid may reduce PTP-MEG1 expression by hyperacetylating histones, thereby altering the chromatin conformation and decreasing the accessibility of the gene to transcriptional machinery.